- The 2nd Menopause & HIV Webinar will take place on Thursday, 23 January 2025 at 16:00 - 17:00 CET.
-
To stay updated on the relevant developments, make sure you are signed up for our newsletter.
2nd Menopause & HIV Webinar 2025
What's New
About this Webinar
Menopause is a transition phase in aging women that is associated with hormonal changes that increase the risk for cardiovascular, bone, and neurocognitive diseases. Women in menopause are also at higher risk of acquiring HIV. However, little is known about the relationship between HIV and menopause.
Women living with HIV enter menopause 3-5 years earlier than those living without the virus. They experience more severe symptoms and show a higher risk for co-morbidities compared to women living without HIV. Severe menopausal symptoms have been associated with reduced quality of life, poorer mental health, and reduced adherence to HIV care.
Overall, monitoring and clinical management of menopause-related comorbidities and symptoms in women living with HIV becomes burdensome when there are limited official guidelines.
To meet this need, this program will gather a diverse audience of researchers, healthcare professionals, pharmacologists, regulatory, and community representatives to increase awareness about the interplay of HIV and menopause. A dialogue will be stimulated with the aim of improving the management of symptoms, co-morbidities, and quality of life in women who experience menopause and are living with HIV.
Program Chair
General Information
- Researchers
- General practitioners
- Gynaecologists
- Pharmacologists
- Regulatory representatives
- Patient community representatives
- Industry representatives
• Increase awareness on challenges faced by women living with HIV and experiencing menopause;
• Stimulate discussion among participants of different backgrounds on appropriate management of conditions that appear in women living with HIV and experiencing menopause.
• Summarize symptoms and other challenges faced by women living with HIV and experiencing menopause;
• Outline latest data on treatment regimens and pharmacological characteristics;
• Reflect on strategies to manage menopausal symptoms in women living with HIV.
Practical Information
Translation will not be provided.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Fees and Conditions
Regular Delegates |
Industry Delegates | |
---|---|---|
Registration Fee | Complimentary | €195 |
The following falls under the ''regular delegates'' category: clinicians, researchers, general practitioners, gynaecologists, pharmacologists, regulatory representatives, patient community representatives.
Important
-
We strongly advise that you register early to ensure your registration.
-
Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.
- Digital workshop pack, including the program.
IMPORTANT:
- Payment can only be made by credit card.
- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
- Cancellation before/on 30 December 2024: 50% refund (minus an administration fee of €40)
- Cancellation after 30 December 2024: Unfortunately, no refund will be given
If you are unable to attend the webinar, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the secretariat has been notified of the name of the substitute delegate before 12 January 2025. A statement (email/letter) of cancellation must be sent to Virology Education.
Preliminary Program
Support
The 2nd Menopause & HIV Webinar 2025 is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.